Valitor has been awarded a Phase I SBIR grant from the National Institute of General Medical Sciences. This project will support the translation of our wound healing platform to a wider range of growth factors and other therapeutic proteins that have demonstrated safety in previous clinical studies. The results of this award will facilitate strategic partnerships and commercialization of our technology.
Valitor is proud to announce the final close of our Series A financing, co-lead by the Berkeley Catalyst Fund and ShangPharma Innovations. This round oversubscribed our initial offering, and we raised
Valitor has been awarded a Phase I SBIR grant from the National Cancer Institute. This project will support validation of our platform technology to generate long-acting immunotherapies that can provi
Valitor has been awarded a Phase I SBIR grant from the National Institute of Arthritis and Musculoskeletal and Skin Diseases. This project will continue the development of a long-acting anti-inflammat